Andabak Rogulj Ana, Brkić Denis, Alajbeg Iva, Džanić Emir, Alajbeg Ivan
Professor Ivan Alajbeg, MD, PhD, University of Zagreb School of Dental Medicine , Department of Oral Medicine, Gundulićeva 5 , 10 000 Zagreb , Croatia;
Acta Dermatovenerol Croat. 2014;22(4):250-8.
"Non-Aromatic Very rich in Steranes" (NAVS) naphthalan is a purified natural oil derivative, abundant in steranes (geogenic "steroids"). The purpose of this study was to evaluate the effectiveness of NAVS in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). We used NAVS oil in adhesive paste in 11 patients with clinically and histologically proven OLP (open label), and in 7 patients with RAS (double blind randomized; topical betamethasone in adhesive paste used as control). The severity of the OLP lesions was objectively scored. The number and diameter of RAS lesions were assessed on days 0, 3, and 5. The intensity of pain and discomfort was determined using visual analogue scale (VAS) and "Oral health impact profile" (OHIP-14) before and after therapy. OLP cumulative activity scores on days 0 and 28 were 101.5 and 48.5, respectively (t=5.99; P=0.0001). Using NAVS for 28 days resulted in 52.2% overall clinical improvement. Cumulative OHIP-14 scores on days 0 and 28 were 210 and 142, respectively (t=5.65; P=0.0002). Out of a total of 7 patients with RAS, 4 of them were treated with NAVS and 3 with topical corticosteroids. There were no statistically significant differences in improvement rate between the two groups (lesion number (day 3 P=0.29; day 5 P=0.32); lesion diameter (day 3 P=0.64; day 5 P=0.74)). NAVS successfully reduced the clinical signs and symptoms of OLP, and reduced the number, diameter, and symptoms in patients with RAS, statistically comparable with corticosteroids.
“非芳香族富含甾烷”（NAVS）萘满是一种纯化的天然油衍生物，富含甾烷（地质成因的“类固醇”）。本研究的目的是评估NAVS治疗口腔扁平苔藓（OLP）和复发性阿弗他口炎（RAS）的有效性。我们将NAVS油制成黏附糊剂，用于11例经临床和组织学证实的OLP患者（开放标签），以及7例RAS患者（双盲随机；黏附糊剂中的外用倍他米松用作对照）。对OLP病变的严重程度进行客观评分。在第0、3和5天评估RAS病变的数量和直径。在治疗前后使用视觉模拟量表（VAS）和“口腔健康影响量表”（OHIP - 14）确定疼痛和不适的强度。第0天和第28天的OLP累积活动评分分别为101.5和48.5（t = 5.99；P = 0.0001）。使用NAVS治疗28天导致总体临床改善率为52.2%。第0天和第28天的OHIP - 14累积评分分别为210和142（t = 5.65；P = 0.0002）。在总共7例RAS患者中，4例接受NAVS治疗，3例接受外用皮质类固醇治疗。两组之间的改善率没有统计学上的显著差异（病变数量（第3天P = 0.29；第5天P = 0.32）；病变直径（第3天P = 0.64；第5天P = 0.74））。NAVS成功减轻了OLP的临床体征和症状，并减少了RAS患者的病变数量、直径和症状，在统计学上与皮质类固醇相当。
